3/29/2012

Bristol-Myers Squibb offered to purchase Amylin Pharmaceuticals for $3.5 billion, sources said, but
Amylin rejected the unsolicited bid. Analysts said Amylin, which makes diabetes medicines Byetta and Bydureon, might attract a bigger transaction from AstraZeneca or another company looking to augment its pipeline.

Full Story:
Bloomberg

Related Summaries